Comparison of effect sizes associated with biomarkers reported in highly cited individual articles and in subsequent meta-analyses

JAMA

Volumn 305, Issue 21, 2011, Pages 2200-2210

  Ioannidis, John P A ^a   Panagiotou, Orestis A ^b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF IOANNINA   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER;

DATA EXTRACTION; DISEASE COURSE; MEDICAL LITERATURE; PRIORITY JOURNAL; PUBLICATION; REVIEW; RISK ASSESSMENT; RISK FACTOR; SAMPLE SIZE; STATISTICAL ANALYSIS; SYSTEMATIC REVIEW; ARTICLE; COMPARATIVE STUDY; EQUIPMENT; HUMAN; META ANALYSIS (TOPIC);

BIOLOGICAL MARKERS; DATA INTERPRETATION, STATISTICAL; EFFECT MODIFIERS (EPIDEMIOLOGY); HUMANS; META-ANALYSIS AS TOPIC; RISK ASSESSMENT; SAMPLE SIZE;

EID: 79957789708     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2011.713     Document Type: Review

References (123)

1. Moons KG, Royston P, Vergouwe Y, Grobbee DE, Altman DG. Prognosis and prognostic research. BMJ. 2009;338:b375.
2. Moons KG, Altman DG, Vergouwe Y, Royston P. Prognosis and prognostic research. BMJ. 2009;338:b606.
3. Hlatky MA, Greenland P, Arnett DK, et al; American Heart Association Expert Panel on Subclinical Atherosclerotic Diseases and Emerging Risk Factors and the Stroke Council. Criteria for evaluation of novel markers of cardiovascular risk. Circulation. 2009;119(17):2408-2416.
4. Kyzas PA, Denaxa-Kyza D, Ioannidis JP. Almost all articles on cancer prognostic markers report statistically significant results. Eur J Cancer. 2007;43(17):2559-2579. (Pubitemid 350086938)
5. Kavvoura FK, Liberopoulos G, Ioannidis JP. Selection in reported epidemiological risks. PLoS Med. 2007;4(3):e79.
6. Tzoulaki I, Liberopoulos G, Ioannidis JP. Assessment of claims of improved prediction beyond the Framingham risk score. JAMA. 2009;302(21):2345- 2352.
7. Riley RD, Burchill SA, Abrams KR, et al. A systematic review and evaluation of the use of tumour markers in paediatric oncology. Health Technol Assess. 2003;7(5):1-162.
8. Vergouwe Y, Steyerberg EW, Eijkemans MJ, Habbema JD. Validity of prognostic models. Semin Urol Oncol. 2002;20(2):96-107.
9. Ioannidis JP. Why most discovered true associations are inflated. Epidemiology. 2008;19(5):640-648.
10. Altman DG. Systematic reviews of evaluations of prognostic variables. BMJ. 2001;323(7306):224-228.
11. Kyzas PA, Loizou KT, Ioannidis JP. Selective reporting biases in cancer prognostic factor studies. J Natl Cancer Inst. 2005;97(14):1043-1055. (Pubitemid 41417921)
12. Hayden JA, Côté P, Bombardier C. Evaluation of the quality of prognosis studies in systematic reviews. Ann Intern Med. 2006;144(6):427-437. (Pubitemid 46768164)
13. Kyzas PA, Denaxa-Kyza D, Ioannidis JP. Quality of reporting of cancer prognostic marker studies. J Natl Cancer Inst. 2007;99(3):236-243.
14. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177-188. (Pubitemid 17189972)
15. Ozaki K, Ohnishi Y, Iida A, et al. Functional SNPs in the lymphotoxin-alpha gene that are associated with susceptibility to myocardial infarction. Nat Genet. 2002;32(4):650-654. (Pubitemid 35435179)
16. Giovannucci E, Stampfer MJ, Krithivas K, et al. The CAG repeat within the androgen receptor gene and its relationship to prostate cancer. Proc Natl Acad Sci U S A. 1997;94(7):3320-3323. (Pubitemid 27157309)
17. Grant SF, Thorleifsson G, Reynisdottir I, et al. Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes. Nat Genet. 2006;38(3):320-323.
18. Hageman GS, Anderson DH, Johnson LV, et al. A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration. Proc Natl Acad Sci U S A. 2005;102(20):7227- 7232. (Pubitemid 40696361)
19. Deeb SS, Fajas L, Nemoto M, et al. A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet. 1998;20(3):284-287. (Pubitemid 28507675)
20. Chan JM, Stampfer MJ, Giovannucci E, et al. Plasma insulin-like growth factor-I and prostate cancer risk. Science. 1998;279(5350):563-566. (Pubitemid 28067285)
21. Forman D, Newell DG, Fullerton F, et al. Association between infection with Helicobacter pylori and risk of gastric cancer. BMJ. 1991;302(6788):1302- 1305.
22. Parsonnet J, Friedman GD, Vandersteen DP, et al. Helicobacter pylori infection and the risk of gastric carcinoma. N Engl J Med. 1991;325(16):1127- 1131.
23. Nomura A, Stemmermann GN, Chyou PH, Kato I, Perez-Perez GI, Blaser MJ. Helicobacter pylori infection and gastric carcinoma among Japanese Americans in Hawaii. N Engl J Med. 1991;325(16):1132-1136.
24. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000;342(12):836-843. (Pubitemid 30165206)
25. Danesh J, Wheeler JG, Hirschfield GM, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med. 2004;350(14):1387-1397. (Pubitemid 38419992)
26. Danesh J, Whincup P, Walker M, et al. Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses. BMJ. 2000;321(7255):199-204. (Pubitemid 30459555)
27. Clarke R, Daly L, Robinson K, et al. Hyperhomocysteinemia. N Engl J Med. 1991;324(17):1149-1155.
28. Després JP, Lamarche B, Mauriège P, et al. Hyper-insulinemia as an independent risk factor for ischemic heart disease. N Engl J Med. 1996;334(15):952-957. (Pubitemid 26114161)
29. Lindpaintner K, Pfeffer MA, Kreutz R, et al. A prospective evaluation of an angiotensin-converting-enzyme gene polymorphism and the risk of ischemic heart disease. N Engl J Med. 1995;332(11):706-711.
30. den Heijer M, Koster T, Blom HJ, et al. Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. N Engl J Med. 1996;334(12):759-762. (Pubitemid 26089357)
31. Enomoto N, Sakuma I, Asahina Y, et al. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med. 1996;334(2):77-81. (Pubitemid 26017933)
32. Pallares R, Liñares J, Vadillo M, et al. Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain. N Engl J Med. 1995;333(8):474-480.
33. Hillier SL, Nugent RP, Eschenbach DA, et al; The Vaginal Infections and Prematurity Study Group. Association between bacterial vaginosis and preterm delivery of a low-birth-weight infant.NEngl JMed. 1995;333(26):1737-1742.
34. Braun S, Pantel K, Müller P, et al. Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. N Engl JMed. 2000;342(8):525-533. (Pubitemid 30117892)
35. Weiss EJ, Bray PF, Tayback M, et al. A polymorphism of a platelet glycoprotein receptor as an inherited risk factor for coronary thrombosis. N Engl J Med. 1996;334(17):1090-1094. (Pubitemid 26120186)
36. Higashi MK, Veenstra DL, Kondo LM, et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA. 2002;287(13):1690-1698. (Pubitemid 34289221)
37. Siris ES, Miller PD, Barrett-Connor E, et al. Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women. JAMA. 2001;286(22):2815-2822.
38. Kuipers EJ, Uyterlinde AM, Peña AS, et al. Long-term sequelae of Helicobacter pylori gastritis. Lancet. 1995;345(8964):1525-1528.
39. Pischon T, Girman CJ, Hotamisligil GS, Rifai N, Hu FB, Rimm EB. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA. 2004;291(14):1730-1737. (Pubitemid 38489895)
40. Hankinson SE, Willett WC, Colditz GA, et al. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet. 1998;351 (9113):1393-1396. (Pubitemid 28209997)
41. Ford D, Easton DF, Bishop DT, Narod SA, Goldgar DE; Breast Cancer Linkage Consortium. Risks of cancer in BRCA1-mutation carriers. Lancet. 1994;343(8899):692-695.
42. Stampfer MJ, Malinow MR, Willett WC, et al. A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. JAMA. 1992;268(7):877-881.
43. Toniolo PG, Levitz M, Zeleniuch-Jacquotte A, et al. A prospective study of endogenous estrogens and breast cancer in postmenopausal women. J Natl Cancer Inst. 1995;87(3):190-197.
44. Ma J, Stampfer MJ, Giovannucci E, et al. Methylenetetrahydrofolate reductase polymorphism, dietary interactions, and risk of colorectal cancer. Cancer Res. 1997;57(6):1098-1102. (Pubitemid 27138608)
45. Bell DA, Taylor JA, Paulson DF, Robertson CN, Mohler JL, Lucier GW. Genetic risk and carcinogen exposure: a common inherited defect of the carcinogen-metabolism gene glutathione S-transferase M1 (GSTM1) that increases susceptibility to bladder cancer. J Natl Cancer Inst. 1993;85(14):1159-1164. (Pubitemid 23212283)
46. Wolff MS, Toniolo PG, Lee EW, Rivera M, Dubin N. Blood levels of organochlorine residues and risk of breast cancer. J Natl Cancer Inst. 1993;85(8):648-652. (Pubitemid 23120510)
47. Ma J, Pollak MN, Giovannucci E, et al. Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. J Natl Cancer Inst. 1999;91(7):620-625. (Pubitemid 29194048)
48. Blaser MJ, Perez-Perez GI, Kleanthous H, et al. Infection with Helicobacter pylori strains possessing cagA is associated with an increased risk of developing adenocarcinoma of the stomach. Cancer Res. 1995;55(10):2111-2115.
49. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood. 1996;88(10):3698-3703. (Pubitemid 26383091)
50. Li W, Xu J, Wang X, et al. Lack of association between lymphotoxin-alpha, galectin-2 polymorphisms and coronary artery disease. Atherosclerosis. 2010;208(2):433-436.
51. Zeegers MP, Kiemeney LA, Nieder AM, Ostrer H. How strong is the association between CAG and GGN repeat length polymorphisms in the androgen receptor gene and prostate cancer risk? Cancer Epidemiol Biomarkers Prev. 2004;13(11 pt 1):1765-1771.
52. Tong Y, Lin Y, Zhang Y, et al. Association between TCF7L2 gene polymorphisms and susceptibility to type 2 diabetes mellitus. BMC Med Genet. 2009;10:15.
53. Conley YP, Jakobsdottir J, Mah T, et al. CFH, ELOVL4, PLEKHA1 and LOC387715 genes and susceptibility to age-related maculopathy. Hum Mol Genet. 2006;15(21):3206-3218. (Pubitemid 44605500)
54. Gouda HN, Sagoo GS, Harding AH, Yates J, Sandhu MS, Higgins JP. The association between the peroxisome proliferator-activated receptor-gamma2 (PPARG2) Pro12Ala gene variant and type 2 diabetes mellitus. Am J Epidemiol. 2010;171(6):645-655.
55. Rowlands MA, Gunnell D, Harris R, Vatten LJ, Holly JM, Martin RM. Circulating insulin-like growth factor peptides and prostate cancer risk. Int J Cancer. 2009;124(10):2416-2429.
56. Eslick GD, Lim LL, Byles JE, Xia HH, Talley NJ. Association of Helicobacter pylori infection with gastric carcinoma. Am J Gastroenterol. 1999;94(9):2373-2379. (Pubitemid 29420659)
57. Kaptoge S, Di Angelantonio E, Lowe G, et al; Emerging Risk Factors Collaboration. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality. Lancet. 2010;375(9709):132-140.
58. Cleophas TJ, Hornstra N, van Hoogstraten B, van der Meulen J. Homocysteine, a risk factor for coronary artery disease or not? Am J Cardiol. 2000;86(9):1005-1009.
59. Ruige JB, Assendelft WJ, Dekker JM, Kostense PJ, Heine RJ, Bouter LM. Insulin and risk of cardiovascular disease. Circulation. 1998;97(10):996-1001.
60. Agerholm-Larsen B, Nordestgaard BG, Tybjaerg-Hansen A. ACE gene polymorphism in cardiovascular disease. Arterioscler Thromb Vasc Biol. 2000;20(2):484-492.
61. Den Heijer M, Lewington S, Clarke R. Homocys- teine, MTHFR and risk of venous thrombosis. J Thromb Haemost. 2005;3(2):292-299.
62. Schinkel J, Spaan WJ, Kroes AC. Meta-analysis of mutations in the NS5A gene and hepatitis C virus resistance to interferon therapy. Antivir Ther. 2004;9(2):275-286. (Pubitemid 38560220)
63. Tleyjeh IM, Tlaygeh HM, Hejal R, Montori VM, Baddour LM. The impact of penicillin resistance on short-term mortality in hospitalized adults with pneumococcal pneumonia. Clin Infect Dis. 2006;42(6):788-797. (Pubitemid 43363934)
64. Leitich H, Kiss H. Asymptomatic bacterial vaginosis and intermediate flora as risk factors for adverse pregnancy outcome. Best Pract Res Clin Obstet Gynaecol. 2007;21(3):375-390. (Pubitemid 46825482)
65. Braun S, Vogl FD, Naume B, et al. A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med. 2005;353(8):793-802. (Pubitemid 41215488)
66. Di Castelnuovo A, de Gaetano G, Donati MB, Iacoviello L. Platelet glycoprotein receptor IIIa polymorphism PLA1/PLA2 and coronary risk. Thromb Haemost. 2001;85(4):626-633.
67. Sanderson S, Emery J, Higgins J. CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients. Genet Med. 2005;7(2):97-104.
68. Johnell O, Kanis JA, Oden A, et al. Predictive value of BMD for hip and other fractures. J Bone Miner Res. 2005;20(7):1185-1194. (Pubitemid 40863806)
69. Adamu MA, Weck MN, Gao L, Brenner H. Incidence of chronic atrophic gastritis. Eur J Epidemiol. 2010;25(7):439-448.
70. Sattar N, Wannamethee G, Sarwar N, et al. Adiponectin and coronary heart disease. Circulation. 2006;114(7):623-629.
71. Key TJ, Appleby PN, Reeves GK, Roddam AW; Endogenous Hormones and Breast Cancer Collaborative Group. Insulin-like growth factor 1 (IGF1), IGF binding protein 3 (IGFBP3), and breast cancer risk. Lancet Oncol. 2010;11(6):530-542.
72. Friedenson B. BRCA1 and BRCA2 pathways and the risk of cancers other than breast or ovarian. MedGenMed. 2005;7(2):60.
73. Humphrey LL, Fu R, Rogers K, Freeman M, Helfand M. Homocysteine level and coronary heart disease incidence. Mayo Clin Proc. 2008;83(11):1203-1212.
74. Key T, Appleby P, Barnes I, Reeves G; Endogenous Hormones and Breast Cancer Collaborative Group. Endogenous sex hormones and breast cancer in postmenopausal women. J Natl Cancer Inst. 2002;94(8):606-616. (Pubitemid 34498648)
75. Taioli E, Garza MA, Ahn YO, et al. Meta- and pooled analyses of the methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism and colorectal cancer. Am J Epidemiol. 2009;170(10):1207-1221.
76. García-Closas M, Malats N, Silverman D, et al. NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer. Lancet. 2005;366(9486):649-659.
77. López-Cervantes M, Torres-Sánchez L, Tobías A, López-Carrillo L. Dichlorodiphenyldichloroethane burden and breast cancer risk. Environ Health Perspect. 2004;112(2):207-214.
78. Rinaldi S, Cleveland R, Norat T, et al. Serum levels of IGF-I, IGFBP-3 and colorectal cancer risk. Int J Cancer. 2010;126(7):1702-1715.
79. Huang JQ, Zheng GF, Sumanac K, Irvine EJ, Hunt RH. Meta-analysis of the relationship between cagA seropositivity and gastric cancer. Gastroenterology. 2003;125(6):1636-1644. (Pubitemid 37500427)
80. Gohil R, Peck G, Sharma P. The genetics of venous thromboembolism. Thromb Haemost. 2009;102(2):360-370.
81. Edwards SM, Badzioch MD, Minter R, et al. Androgen receptor polymorphisms. Int J Cancer. 1999;84(5):458-465.
82. Severi G, Morris HA, MacInnis RJ, et al. Circulating insulin-like growth factor-I and binding protein-3 and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev. 2006;15(6):1137-1141.
83. Sipponen P, Riihelä M, Hyvärinen H, Seppälä K. Chronic nonatropic ("superficial") gastritis increases the risk of gastric carcinoma. Scand J Gastroenterol. 1994;29(4):336-340. (Pubitemid 24128381)
84. Wu AH, Crabtree JE, Bernstein L, et al. Role of Helicobacter pylori CagA+ strains and risk of adenocarcinoma of the stomach and esophagus. Int J Cancer. 2003;103(6):815-821. (Pubitemid 36110240)
85. Evans HS, Lewis CM, Robinson D, Bell CM, Møller H, Hodgson SV. Incidence of multiple primary cancers in a cohort of women diagnosed with breast cancer in southeast England. Br J Cancer. 2001;84(3):435-440. (Pubitemid 32154442)
86. Ulvik A, Vollset SE, Hansen S, Gislefoss R, Jellum E, Ueland PM. Colorectal cancer and the methylenetetrahydrofolate reductase 677C->T and methionine synthase 2756A->G polymorphisms. Cancer Epidemiol Biomarkers Prev. 2004;13(12):2175-2180.
87. Rinaldi S, Peeters PH, Berrino F, et al. IGF-I, IGFBP-3 and breast cancer risk in women. Endocr Relat Cancer. 2006;13(2):593-605.
88. Millikan R, DeVoto E, Duell EJ, et al. Dichlorodiphenyldichloroethene, polychlorinated biphenyls, and breast cancer among African-American and white women in North Carolina. Cancer Epidemiol Biomarkers Prev. 2000;9(11):1233-1240.
89. Dorgan JF, Longcope C, Stephenson HE Jr, et al. Relation of prediagnostic serum estrogen and androgen levels to breast cancer risk. Cancer Epidemiol Biomarkers Prev. 1996;5(7):533-539. (Pubitemid 26235020)
90. Diel IJ, Kaufmann M, Costa SD, et al. Micrometastatic breast cancer cells in bone marrow at primary surgery. J Natl Cancer Inst. 1996;88(22):1652-1658.
91. Clarke R, Xu P, Bennett D, et al; International Study of Infarct Survival (ISIS) Collaborators. Lymphotoxin-alpha gene and risk of myocardial infarction in 6,928 cases and 2,712 controls in the ISIS case-control study. PLoS Genet. 2006;2(7):e107.
92. Stehouwer CD, Weijenberg MP, van den Berg M, Jakobs C, Feskens EJ, Kromhout D. Serum homocysteine and risk of coronary heart disease and cerebrovascular disease in elderly men. Arterioscler Thromb Vasc Biol. 1998;18(12):1895-1901.
93. Møller LF, Jespersen J. Fasting serum insulin levels and coronary heart disease in a Danish cohort. J Cardiovasc Risk. 1995;2(3):235-240.
94. Agerholm-Larsen B, Nordestgaard BG, Steffensen R, Sørensen TI, Jensen G, Tybjaerg-Hansen A. ACE gene polymorphism: ischemic heart disease and longevity in 10,150 individuals. Circulation. 1997;95(10):2358-2367.
95. Gardemann A, Humme J, Stricker J, et al. Association of the platelet glycoprotein IIIa PlA1/A2 gene polymorphism to coronary artery disease but not to nonfatal myocardial infarction in low risk patients. Thromb Haemost. 1998;80(2):214-217. (Pubitemid 28393610)
96. Arnesen E, Refsum H, Bønaa KH, Ueland PM, Førde OH, Nordrehaug JE. Serum total homocysteine and coronary heart disease. Int J Epidemiol. 1995;24(4):704-709.
97. Tsai AW, Cushman M, Tsai MY, et al. Serum homocysteine, thermolabile variant of methylene tetrahydrofolate reductase (MTHFR), and venous thromboembolism. Am J Hematol. 2003;72(3):192-200.
98. Emmerich J, Rosendaal FR, Cattaneo M, et al; Study Group for Pooled-Analysis in Venous Thromboembolism. Combined effect of factor V Leiden and prothrombin 20210A on the risk of venous thromboembolism. Thromb Haemost. 2001;86(3):809-816.
99. Kimber CH, Doney AS, Pearson ER, et al. TCF7L2 in the Go-DARTS study. Diabetologia. 2007;50(6):1186-1191.
100. Zeggini E, Weedon MN, Lindgren CM, et al; Wellcome Trust Case Control Consortium (WTCCC). Replication of genome-wide association signals in UK samples reveals risk loci for type 2 diabetes. Science. 2007;316(5829):1336-1341.
101. Margaglione M, Colaizzo D, D'Andrea G, et al. Genetic modulation of oral anticoagulation with warfarin. Thromb Haemost. 2000;84(5):775-778.
102. Pallares R, Capdevila O, Liñares J, et al. The effect of cephalosporin resistance on mortality in adult patients with nonmeningeal systemic pneumococcal infections. Am J Med. 2002;113(2):120-126. (Pubitemid 34804748)
103. Meis PJ, Goldenberg RL, Mercer B, et al; National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. The preterm prediction study. Am J Obstet Gynecol. 1995;173(4):1231-1235.
104. Rivera A, Fisher SA, Fritsche LG, et al. Hypothetical LOC387715 is a second major susceptibility gene for age-related macular degeneration, contributing independently of complement factor H to disease risk. Hum Mol Genet. 2005;14(21):3227-3236. (Pubitemid 41631297)
105. Ozasa K, Kurata JH, Higashi A, et al. Helicobacter pylori infection and atrophic gastritis. Dig Dis Sci. 1999;44(2):253-256.
106. Easterbrook PJ, Berlin JA, Gopalan R, Matthews DR. Publication bias in clinical research. Lancet. 1991;337(8746):867-872.
107. Dwan K, Altman DG, Arnaiz JA, et al. Systematic review of the empirical evidence of study publication bias and outcome reporting bias. PLoS One. 2008;3(8):e3081.
108. Egger M, Schneider M, Davey Smith G. Spurious precision? BMJ. 1998;316(7125):140-144.
109. Thompson S, Ekelund U, Jebb S, et al. A proposed method of bias adjustment for meta-analyses of published observational studies [published online April 21, 2011]. Int J Epidemiol. doi:10.1093/ije/dyq248.
110. Greenland S, Copas J, Jones DR, et al. Multiple-bias modelling for analysis of observational data. J R Stat Soc Ser A Stat Soc. 2005;168(2):267-306. (Pubitemid 40427711)
111. Salanti G, Ioannidis JP. Synthesis of observational studies should consider credibility ceilings. J Clin Epidemiol. 2009;62(2):115-122.
112. Ioannidis JP. Why most published research findings are false. PLoS Med. 2005;2(8):e124.
113. Fock KM, Katelaris P, Sugano K, et al; Second Asia-Pacific Conference. Second Asia-Pacific Consensus Guidelines for Helicobacter pylori infection. J Gastroenterol Hepatol. 2009;24(10):1587-1600.
114. Ioannidis JP. Personalized genetic prediction. Ann Intern Med. 2009;150(2):139-141.
115. Eckman MH, Rosand J, Greenberg SM, Gage BF. Cost-effectiveness of using pharmacogenetic information in warfarin dosing for patients with nonvalvular atrial fibrillation. Ann Intern Med. 2009;150(2):73-83.
116. Vasan RS. Biomarkers of cardiovascular disease. Circulation. 2006;113(19):2335-2362.
117. Hackam DG, Anand SS. Emerging risk factors for atherosclerotic vascular disease. JAMA. 2003;290(7):932-940.
118. Ioannidis JP, Tzoulaki I. What makes a good predictor? JAMA. 2010;303(16):1646-1647.
119. Greenberg SA. How citation distortions create unfounded authority. BMJ. 2009;339:b2680.
120. Kjaergard LL, Gluud C. Citation bias of hepatobiliary randomized clinical trials. J Clin Epidemiol. 2002;55(4):407-410. (Pubitemid 34240493)
121. Ross D, Whitehead M, Stevenson J. Use of hormone replacement therapy. BMJ. 1996;313(7058):686-687.
122. Ravnskov U. Cholesterol lowering trials in coronary heart disease. BMJ. 1992;305(6844):15-19.
123. Rifai N, Altman DG, Bossuyt PM. Reporting bias in diagnostic and prognostic studies. Clin Chem. 2008;54(7):1101-1103. (Pubitemid 352009682)